Lipid Metabolism and Lipoprotein Analysis

Lipid metabolism and lipoprotein analysis is the laboratory measurement of circulating lipids and the particles that transport them — total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and related markers such as apolipoprotein B and lipoprotein(a). These measures characterise lipid transport and cardiovascular risk.

Definition

Lipid metabolism and lipoprotein analysis is the measurement and interpretation of plasma lipids and lipoprotein fractions used to characterise lipid transport and to estimate atherosclerotic cardiovascular risk.

Scope

The topic covers the standard lipid profile, the lipoprotein particles that carry cholesterol and triglycerides, how LDL-C is measured or calculated, and emerging markers such as apolipoprotein B. It is framed as a laboratory-medicine reference and does not provide treatment targets or lipid-lowering recommendations for individuals.

Core questions

• What lipoprotein particles transport cholesterol and triglycerides in plasma?
• How is LDL cholesterol calculated and when does the calculation become unreliable?
• Why might particle-based markers such as apolipoprotein B add information beyond LDL-C?
• How does fasting status affect a lipid profile?

Key concepts

• Total cholesterol and triglycerides
• LDL cholesterol and HDL cholesterol
• Friedewald estimation of LDL-C
• Apolipoprotein B and non-HDL cholesterol
• Lipoprotein(a)
• Fasting versus non-fasting sampling
• Lipoprotein particle versus cholesterol mass

Mechanisms

Lipids are insoluble in plasma and are carried within lipoprotein particles distinguished by density and apolipoprotein content. The standard panel measures total cholesterol, triglycerides, and HDL-C directly, with LDL-C commonly calculated by the Friedewald equation, which subtracts HDL-C and an estimate of very-low-density-lipoprotein cholesterol from total cholesterol and loses accuracy at high triglyceride levels (friedewald-1972; rifai-tietz-2017). Because each LDL particle carries one apolipoprotein B molecule, apolipoprotein B and non-HDL cholesterol capture the number of atherogenic particles, which can diverge from LDL-C mass. The causal relationship between LDL-bearing lipoproteins and atherosclerosis underlies the use of these markers in risk assessment (silverman-2016).

Clinical relevance

Lipid profiles are used in cardiovascular risk assessment and in monitoring lipid-modifying interventions. This entry explains what the measured fractions represent and how they are derived; it is a reference resource and does not state target values or recommend therapy for any individual.

Evidence & guidelines

Lipid measurement and its role in cardiovascular risk are addressed by dyslipidaemia guidelines (mach-2020) and by evidence linking LDL-C lowering to risk reduction across interventions (silverman-2016); the calculation of LDL-C follows the long-standing Friedewald approach with its recognised limitations (friedewald-1972; rifai-tietz-2017).

Debates

Should apolipoprotein B or non-HDL cholesterol supersede LDL-C?

Particle-based markers such as apolipoprotein B count atherogenic lipoproteins directly and may better capture risk when LDL-C and particle number diverge, but LDL-C remains the most widely measured and reported quantity.

Seminal works

• friedewald-1972
• mach-2020

Frequently asked questions

Is LDL cholesterol measured directly or calculated?

It is most often calculated from total cholesterol, HDL-C, and triglycerides using the Friedewald equation; direct measurement is used when triglycerides are high or fasting is uncertain, conditions under which the calculation is less reliable.

Why are apolipoprotein B and non-HDL cholesterol of interest?

They reflect the number of atherogenic lipoprotein particles rather than only cholesterol mass, which can give additional information when particle number and LDL-C diverge.